This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plotnick, L.
Right arrow Articles by Sy, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plotnick, L.
Right arrow Articles by Sy, J. P.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 102 No. 2 Supplement August 1998, pp. 479-481

Growth Hormone Treatment of Girls With Turner Syndrome: The National Cooperative Growth Study Experience

Received Feb 6, 1998; accepted Mar 20, 1998.

Leslie Plotnick*, Kenneth M. AttieDagger , Sandra L. BlethenDagger , and Judy P. SyDagger

From the * Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland; and the Dagger  Department of Medical Affairs, Genentech Inc, South San Francisco, California.

Objective.  To evaluate growth rate and adult height with recombinant growth hormone (GH) treatment in girls with Turner syndrome (TS) and predictors of their growth response.

Methods.  Data on girls with TS who were treated with GH in the National Cooperative Growth Study (NCGS) were evaluated. As of January 1997, there were 2798 girls with TS in the NCGS database, 2652 of whom had not previously received GH. Follow-up data on growth were available for 2475 subjects, and data on adult height were available for 622.

Results.  The average age of girls with TS at enrollment in the NCGS was 10.1 ± 3.6 years. These patients had severely short stature compared with that of unaffected American girls (height, 118.5 ± 16.5 cm; height standard deviation score [SDS], -3.1 ± 0.9), but their heights were typical of those of American girls with TS (TS-specific height SDS, 0.01 ± 0.9). Treatment with GH for an average duration of 3.2 ± 2.0 years resulted in an increase in height SDS of 0.8 ± 0.7 compared with unaffected girls and of 1.2 ± 0.8 compared with TS standards. Growth rates increased from 4.0 ± 2.3 cm/year before treatment to 7.5 ± 2.0 cm/year after 1 year of treatment. Duration of treatment with GH was the strongest predictor of change in height SDS. After 6 to 7 years of treatment with GH, there was a cumulative change of 2.0 in mean height SDS.

The 622 girls who reached adult height were older when they began taking GH. Their mean height gain over pre-GH projected height was 6.4 ± 4.9 cm after 3.7 ± 1.9 years of treatment. Their adult height was 148.3 ± 5.6 cm.

Conclusions.  Although the response to treatment with GH varied, it was associated with highly significant gains in growth and adult height in girls with TS. Duration of treatment with GH was the most important variable predicting adult height.

Key words: Turner syndrome, growth hormone, growth.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. Bolar, A. R. Hoffman, T. Maneatis, and B. Lippe
Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 344 - 351.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Soriano-Guillen, J. Coste, E. Ecosse, J. Leger, M. Tauber, S. Cabrol, M. Nicolino, R. Brauner, the StaTur Study Group, J.-L. Chaussain, et al.
Adult Height and Pubertal Growth in Turner Syndrome after Treatment with Recombinant Growth Hormone
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5197 - 5204.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
V. P. Sybert and E. McCauley
Turner's Syndrome
N. Engl. J. Med., September 16, 2004; 351(12): 1227 - 1238.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. A. Rappold, M. Fukami, B. Niesler, S. Schiller, W. Zumkeller, M. Bettendorf, U. Heinrich, E. Vlachopapadoupoulou, T. Reinehr, K. Onigata, et al.
Deletions of the Homeobox Gene SHOX (Short Stature Homeobox) Are an Important Cause of Growth Failure in Children with Short Stature
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1402 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, S. L. Blethen, J. Baptista, and L. Price
Early Initiation of Growth Hormone Treatment Allows Age-Appropriate Estrogen Use in Turner's Syndrome
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1936 - 1941.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. E. Hale, J. D. Cody, J. Baillargeon, R. Schaub, M. M. Danney, and R. J. Leach
The Spectrum of Growth Abnormalities in Children with 18q Deletions
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4450 - 4454.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Guyda
Four Decades of Growth Hormone Therapy for Short Children: What Have We Achieved?
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4307 - 4316.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
Growth-Promoting Strategies in Turner's Syndrome
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4345 - 4348.
[Full Text]

Home page
 PediatricsHome page
F. R. Kaufman and J. P. Sy
Regular Monitoring of Bone Age Is Useful in Children Treated With Growth Hormone
Pediatrics, October 1, 1999; 104(4): 1039 - 1042.
[Abstract] [Full Text]